Additionally, they observed that ATRA and decitabine inhibited DNMT1, activated miR-34a via promoter hypomethylation, down-regulated its MYCN target, and therefore exhibited a synergistic anti-cancer action. This evidence concerns the gene DNMT1 and cancer.